Prescription frequency and patterns of Chinese herbal medicine for liver cancer patients in Taiwan: a cross-sectional analysis of the National Health Insurance Research Database by unknown
RESEARCH ARTICLE Open Access
Prescription frequency and patterns of
Chinese herbal medicine for liver cancer
patients in Taiwan: a cross-sectional
analysis of the National Health Insurance
Research Database
Chin-Tsung Ting1,2, Chian-Jue Kuo3,4, Hsiao-Yun Hu5,8, Ya-Ling Lee5,6,7* and Tung-Hu Tsai1,8*
Abstract
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide.
Chinese herbal medicine (CHM) is frequently provided to HCC patients. The aim of this study was to understand
the prescription frequency and patterns of CHM for HCC patients by analyzing the claims data from the National
Health Insurance (NHI) in Taiwan.
Methods: We identified 73918 newly diagnosed HCC subjects from the database of Registry for Catastrophic Illness
during 2002 to 2009 and to analyze the frequency and pattern of corresponding CHM prescriptions for HCC patients.
Results: There were a total of 685,079 single Chinese herbal prescriptions and 553,952 Chinese herbal formula
prescriptions used for 17,373 HCC subjects before 2 years of HCC diagnosis. Among the 13,093 HCC subjects
who used CHMs after HCC diagnosis, there were 462,786 single Chinese herbal prescriptions and 300,153 Chinese herbal
formula prescriptions were counted. By adjusting with person-year and ratio of standardized incidence rate, the top ten
prescribed single herbal drugs and Chinese herbal formulas for HCC patients were described in our study. Among them,
we concluded that, Oldenlandia diffusa (Chinese herbal name: Bai-Hua-She-She-Cao), Radix et Rhizoma Rhei (Da Huang)
and the herbal preparation of Xiao-Chai-Hu-Tang and Gan-Lu-Yin, were the most obviously increased and important
CHMs been used for HCC patients.
Conclusion: We established an accurate and validated method for the actual frequency and patterns of CHM use in
treating HCC in Taiwan. We propose that these breakthrough findings may have important implications for HCC therapy,
clinical trials and modernization of CHM.
Keywords: Hepatocellular carcinoma, Chinese herbal medicine, National health insurance, Single herbal drug, Chinese
herbal formula
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Background
Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the third leading cause of cancer-related deaths
worldwide [1]. According to「The International Agency
for Research On Cancer: GLOBOCAN 2008」 report, the
regions of high incidence are Eastern and South-Eastern
Asia, Middle and Western Africa [2]. The incidence rate of
HCC has been on an exponential rise, tripling between
1975 and 2005 and increasing from 1.6 to 4.9 per 100,000
individuals [3]. The age-adjusted incidence rates and trend
of liver cancer in Taiwan is similar to that observed in the
other regions [4]. The etiologies of HCC, including chronic
hepatitis B or C infection, cirrhosis, non-alcoholic fatty
liver disease, alcohol induced liver disease, and exposure to
aflatoxin and other carcinogens [5], is suggested to be re-
sponsible for acute and chronic liver cirrhosis leading con-
sequently to development of HCC [6].
Hepatic resection remains one of the most common,
effective, and widely accepted therapeutic interventions
for patients with HCC [7, 8]. However, less than 30% of
patients with HCC met the criteria of curative hepatic
resection [9]. The five-year recurrence rate of HCC in
patients undergoing curative treatment, such as hepatic
resection, can be up to 70% [10, 11]. As a result, the low
curative resection rate and high recurrence factors are
result in high cancer-related mortality and notorious for
poor prognosis. Most newly diagnosed or recurrent
HCC patients, who cannot meet the criteria of curative
therapies, need further adjuvant therapies, such as trans-
arterial chemoembolization, chemotherapy and radio-
therapy [9]. Despite the advantages of treating subjects
with HCC using Western medicine, the five-year survival
is dismal. Therefore, a remarkable number of HCC
patients use CHM and conventional Western medicine
concurrently, or persisted in using CHM after HCC
diagnosis clinically. The reasons may possibly be due to
their culture, trying to increase the therapeutic effects of
conventional Western medicine, the higher incidence of
the concomitant chronic hepatitis and cirrhosis, or the
concern of the side effects of conventional Western
medicine [12, 13].
CHM has been used for HCC for over a thousand
years, and been proven to be an efficacious and safe
treatment option for chronic hepatitis and cirrhosis in
some clinical trials [14, 15]. Some CHMs have wealth of
experience in preventing and treating HCC [16], and
also been proven effective for HCC in vitro studies [17].
However, despite the fact that a variety of the CHMs
have been used to treat HCC based on physician’s em-
pirical experiences, it remains unclear what kind of
Chinese herbal drugs or formulae used would be pos-
sibly effectual in treating HCC. Furthermore, there is no
extensive epidemiological and evidence-base study
evaluating the frequency and pattern of CHM use for
HCC. Therefore, it is hard to reach a consensus or es-
tablish a general guideline of CHM prescription for
treatment of HCC. Thus, it is important to identify the
potentially effective herbs from the variety of widely-
used CHM in clinical practice.
National health insurance (NHI), the only national and
official health insurance program in Taiwan was estab-
lished in 1995, and covers nearly all inhabitants
(22,134,270 beneficiaries at the end of 2004, covering
nearly 98% of the total population in Taiwan) [18].
People in Taiwan are free to choose Western medicine
or CHM, and are allowed to visit primary care clinics or
hospitals without referral. In addition, all CHMs are pro-
vided only in ambulatory clinics under the coverage of
NHI and there is no inpatient care and only licensed
Traditional Chinese Medicine physicians are qualified
for reimbursement. Therefore, the NHI claims database
would seem to provide an ideal platform for a pharma-
coepidmiological study and a large-scale survey of drug
utilization and prescribing patterns of CHM. The aim of
this study is to survey the frequency and patterns of
CHM use in the patients two years before and after
HCC diagnosis by analyzing the NHI database.
Methods
Study Samples
The newly diagnosed HCC patients were identified in
data of Registry for Catastrophic Illness Patients with
diagnosis of liver cancer, International Classification of
Diseases, Ninth Revision, Clinical modification (ICD-9-
CM) code 155, of the Bureau of the NHI from 2002 to
2009. All newly diagnosed HCC patients were then re-
trieved from the data sets of claims of ambulatory care.
To obtain demographic data, claim data of ambulatory
care were linked with files of registry for beneficiaries
(ID) by their identifications and dates of birth. The data
on patient identities and institutions had been scrambled
cryptographically for privacy protection. To compare the
frequency and patterns of CHM use for subjects with
newly diagnosed HCC, data extraction, linkage, and ana-
lysis were performed cross-sectional year by year from
2002 to 2009.
Study design
All HCC subjects were then divided into 2 groups: (1)
patients who had used CHMs two years before HCC
diagnosis and (2) patients who had not used CHMs two
years before HCC diagnosis. Furthermore, the group (1)
patients are classified into group (1-A) patients who
continuously used CHMs after HCC diagnosis for two
years. (1-B) patients who had not use CHMs after HCC
diagnosis for two years. The group (2) patients are also
classified into group (2-A) patients who started using
CHMs after HCC diagnosis for two years and (2-B)
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patients who never used CHMs before and after HCC
diagnosis (Fig. 1).
The Chinese herbal medicine used by Chinese medi-
cine Physicians is divided into single herbal drug and
Chinese herbal formula. Chinese herbal formula is a spe-
cial way of CHM prescription. They are traditional made
based on compability characteristics of a variety of single
herbal drugs. Based on meridian and meridian-associated
zàng-organ theory, the Chinese medicine physicians
choose the usage of single herbal drug or Chinese herbal
formula according to the “diagnostic standards of Chinese
medical patterns”, “yin and yang”, “excess or deficiency
syndrome” of the patients and “characteristics” of the
drugs. Thus, the Chinese medicine Physicians expect the
Chinese herbal formula could reduce side effects and
expand the efficacy of drugs, and also meet the needs
of therapeutic effect of complexities of the disease.
Therefore, according the prescription patterns of
Chinese medicine Physicians, we divided the prescrip-
tions of CHMs into single herbal drug and Chinese
herbal formula in our study.
The definition of「ever CHM use」was defined as at
least two CHM clinic visits. Claims with diagnosis code of
HCC were defined as cancer-specific visits. Claims with-
out a diagnosis code of HCC were defined as non cancer-
specific visits. Patients who had used cancer-specific visits
were defined as cancer-specific users. Patients who had
never used cancer-specific visits were defined as non-
cancer-specific users.
Statistics
Demographic characteristics of newly diagnosed HCC
patients were examined. The prevalence of CHM use in
each cross sectional year was calculated. Visit frequency,
medical institutes, and patterns of therapies from 2002
to 2009 were examined. The utilization frequency and
patterns of cancer-specific CHM visits two years before
and after HCC diagnosis were compared. The data were
analyzed using SAS for Windows Version 9.4 (SAS Insti-
tute Inc., Cary, NC). The distribution and frequency of
each category of variables were examined by χ2 tests. A
P value of < 0.05 was considered statistically significant.
Results
During 2002–2009, a total of 73,918 newly diagnosed
HCC patients were identified in the database of Registry
for Catastrophic Illness. The incidence of HCC develop-
ment is more frequent in male subjects than female sub-
jects with a ratio 2.5 (male : female = 2.5: 1). The peak
age of subjects with new HCC development was between
Fig. 1 Flow diagram of study subjects selection from the National Health Insurance Research Database (NHIRD) during 2002-2009. Abbreviations:
NHIRD: the National Health Insurance Research Database of Taiwan; HCC: Hepatocellular carcinoma; CHM: Chinese herbal medicine
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50 and 79 years of age (74.8%). There was a steady up-
ward trend in HCC incidence increasing from 8,481 in
2002 to 10,265 in 2009. Among them, 65,937 subjects
(89.2%) had the diagnostic coding of chronic hepatitis
and cirrhosis (ICD-9: 573; 571) and 53,373 subjects
(72.2%) had viral hepatitis (ICD-9: 070). In the mean-
time, the study found 23.5% of patients used CHMs, in-
cluding 20% of single herbal drug and 22.8% Chinese
herbal formula, before HCC diagnosis. The study also
found that 17.7% of patients used CHMs, including
15.3% of single herbal drug and 17.1% of Chinese herbal
formula after HCC diagnosis. The demographics are pre-
sented in Table 1.
Among these HCC subjects, there were a total of
685,079 single Chinese herbal prescriptions and 553,952
Chinese herbal formula prescriptions before 2 years of
HCC diagnosis among the 17,373 HCC subjects who ever
used CHMs before, and there were 462,786 single Chinese
herbal prescriptions and 300,153 Chinese herbal formula
prescriptions after 2 years of HCC diagnosis among the
13,093 HCC subjects who used CHMs after HCC diagno-
sis. Among them, Salvia miltiorrhiza (Chinese herbal
name: Dan-Shen; 2.58%) was the most commonly pre-
scribed single Chinese herbal drug two years before HCC
diagnosis, followed by Corydalis yanhusuo (Yanhusuo:
2.13%), Oldenlandia diffusa (Bai-Hua-She-She-Cao:1.83%),
Scutellaria baicalensis (Huang-Qin:1.51%), Artemisia
capillaris (Yin-Chen-Hao: 1.43%), Fritillaria (Beimu:
1.42%), Astragalus membranaceus (Huang-Qi: 1.26%),
Radix et Rhizoma Rhei (Da Huang: 1.21%), Puerariae
Radix (1.12%) and Polygonum multiflorum Thunb (1.08%),
respectively. For a single Chinese herbal drug prescribed
two years after HCC diagnosis, Salvia miltiorrhiza
(Dan-Shen: 2.49%) was the most commonly prescription
followed by Corydalis yanhusuo (Yanhusuo; 2.45%), Old-
enlandia diffusa (Bai-Hua-She-She-Cao: 1.88%), Artemisia
capillaris (Yin-Chen-Hao: 1.61%), Scutellaria baicalensis
(Huang-Qin:1.61%), Fritillaria (Beimu:1.41%), Radix et
Rhizoma Rhei (Da Huang:1.3%), Scutellariae Barbatae
Herba (Banzhilian: 1.29%), Astragalus membranaceus
Table 1 Baseline characteristics of the newly diagnosed HCC patients, 2002-2009 (n = 73,918)
Variables Male Female Total
(n = 52,860) (n = 21,058) (n = 73,918)
Age
<50 9,830(18.6%) 1,613(7.7%) 11,443(15.5%)
50–79 38,783(73.4%) 16,486(78.3%) 55,269(74.8%)
≥80 4,247(8.0%) 2,959(14.1%) 7,206(9.7%)
The incidence rate/year of HCC
2002 6,122(11.6%) 2,359(11.2%) 8,481(11.5%)
2003 6,110(11.6%) 2,331(11.1%) 8,441(11.4%)
2004 6,346(12.0%) 2,465(11.7%) 8,811(11.9%)
2005 6,570(12.4%) 2,495(11.8%) 9,065(12.3%)
2006 6,528(12.3%) 2,569(12.2%) 9,097(12.3%)
2007 6,922(13.1%) 2,723(12.9%) 9,645(13.0%)
2008 7,100(13.4%) 3,013(14.3%) 10,113(13.7%)
2009 7,162(13.5%) 3,103(14.7%) 10,265(13.9%)
Co-morbidities
Chronic liver disease/cirrhosis (ICD9: 573 &571) 46,866(63.4%) 19,071(25.8%) 65,937(89.2%)
Viral hepatitis (ICD9:070) 37,928(51.3%) 15,445(20.9%) 53,373(72.2%)
CHM prescribed (single or formula)
2 years before HCC diagnosis 11,576(21.9%) 5,797(27.5%) 17,373(23.5%)
2 years after HCC diagnosis 8,711(16.5%) 4,382(20.8%) 13,093(17.7%)
Single Chinese herbs prescribed
2 years before HCC diagnosis 9,771(18.5%) 4,979(23.6%) 14,750(20.0%)
2 years after HCC diagnosis 7,521(14.2%) 3,813(18.1%) 11,334(15.3%)
Chinese herbal formula prescribed
2 years before HCC diagnosis 11,238(21.3%) 5,649(26.8%) 16,887(22.8%)
2 years after HCC diagnosis 8,425(15.9%) 4,251(20.2%) 12,676(17.1%)
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(Huang-Qi:1.08%), Atractylodes macrocephala (Baizhu:
1.08%), respectively.
Jia-Wei-Xia-Yao-San (3.66%) was the most commonly
prescribed Chinese herbal formula two years before HCC
diagnosis, followed by Xiao-Chai-Hu-Tang (2.77%), Long-
Dan-Xie-Gan-Tang (2.33%), Shu-Jing-Hwo-Shiee-Tang
(2.21%), Xiang-Sha-Liu-Jun-Zi-Tang (2.04%), Ping-Wei-
San (1.74%), Sho-Yao-Gan-Cao-Tang (1.72%), Gan-Lu-Yin
(1.7%), Shiee-Fuu-Jwu-Iu-Tang (1.62%) and Chuan-
Chung-Cha-Tiao-San (1.6%), respectively. For a Chinese
herbal formula prescribed two years after HCC diagnosis,
Jia-Wei-Xia-Yao-San (3.89%) was the most commonly pre-
scription followed by Xiao-Chai-Hu-Tang (2.92%), Shu-
Jing-Hwo-Shiee-Tang (2.27%), Xiang-Sha-Liu-Jun-Zi-Tang
(2.07%), Long-Dan-Xie-Gan-Tang (1.96%), Ping-Wei-San
(1.95%), Yin-Chen-Wu- Ling-San (1.73%), Gan-Lu-Yin
(1.65%), Sho-Yao-Gan- Cao-Tang (1.55%) and Chai-Hu-
Su-Gan-Tang (1.08%), respectively.
However, we found a significant reduction of the use
frequency of CHMs after HCC diagnosis. The reason of
reduction may be due to 25.57% of newly diagnosed
HCC patients died within 90 days after HCC diagnosis
and 55.5% of newly diagnosed HCC patients died within
two years after HCC diagnosis. Thus, we measured the
clinical visits by excluding patients of HCC who died
after HCC diagnosis. The definition of patients of HCC
who died after HCC diagnosis was patient who had
cancellation of insurance without further clinical visit.
The result showed up to 34,066 (46.1%) patients died
within one year after HCC diagnosis and 41,021 (55.5%)
patients died within two years after HCC diagnosis. The
cumulative one and two years overall survival was 53.9%
and 44.5%. Our result is reliable when compared with
the cumulative five years overall survival result of the
annual report of Cancer Registry Annual Report (2010)
in Taiwan [19] (Table 2).
To clarify the change of the use frequency and patterns
of CHM before and after HCC diagnosis in HCC patients,
we defined「the number of individual CHM use in HCC
patients every year」 as「frequency of use (every visit)」.
The annual CHM use of surviving HCC patient in the
study interval was defined as 「person-year (py)」. The
contribution of CHM use of surviving HCC patient in the
study interval of person-year was defined as 「standard-
ized incidence rate (IR)」. In accordance with the above
statistical definition, the individual standardized incidence
rate (IR) of CHMs use of newly diagnosed HCC patients
before and after HCC diagnosis was calculated. We com-
pared the individual standardized incidence rate (IR) of
CHMs use before and after HCC diagnosis, and the results
showed the standardized incidence ratio (the ratio of stan-
dardized incidence rate ((IRR)); IRafter/IRbefore) of CHMs
use before and after HCC diagnosis. Therefore, we used
the standardized incidence rate ratio (IRR) to adjust the
frequency and patterns of individual CHM use in HCC
patients before and after HCC diagnosis. By comparing
the standardized incidence rate ratio (IRR) obtained before
and after HCC diagnosis, our studies revealed a significant
increasing proportion of frequency in CHM use two years
after HCC diagnosis, no matter single Chinese herbs or
Chinese herbal formula (P < 0.001) (table 3).
By adjusting with IRR, the increasing proportion of
frequency of the top 10 single Chinese herbs prescribed
after HCC diagnosis were listed as: Oldenlandia diffusa
(Bai-Hua-She-She-Cao; IRR:2.5), Radix et Rhizoma Rhei
(Da Huang; IRR:2.17), Artemisia capillaris (Yin-Chen-
Hao; IRR:2.11), Scutellaria baicalensis (Huang-Qin;
IRR:1.99), Astragalus membranaceus (Huang-Qi; IRR:1.9),
Polygonum multiflorum Thunb (IRR:1.87), Salvia miltior-
rhiza (Dan-Shen; IRR:1.8), Puerariae Radix (IRR:1.79),
Fritillaria (Beimu; IRR:1.72), Corydalis yanhusuo (Yanhu-
suo; IRR:1.64). By comparing the increasing proportion
ratio, the usage frequency of Oldenlandia diffusa (Bai-
Hua-She-She-Cao) and Radix et Rhizoma Rhei (Da
Huang) was significantly increased after HCC diagnosis
(Table 3).
Furthermore, the increasing proportion of frequency of
the top 10 Chinese herbal formula prescribed after HCC
diagnosis according to IRR were listed as: Ping-Wei-San
(IRR:1.97), Xiang-Sha-Liu-Jun-Zi-Tang (IRR:1.96), Jia-Wei-
Table 2 The survival period and case number of death after HCC diagnosis (n = 73,918)
Survival period The cumulative expired numbers
after HCC diagnosis
Days n % Cumulative n. Cumulative %
0–90 18,900 25.57 18,900 25.57
91–365 15,166 20.52 34,066 46.1
366–730 6,955 9.41 41,021 55.5
Total patients died after 2 years 8985 50,006 67.6
Total cumulative number of patients died 50,006 67.6
Total cumulative number of patients alived 23,912 32.4
Total number of HCC patients 73,918 100
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Xia-Yao-San (IRR:1.87), Xiao-Chai-Hu-Tang (IRR:1.86),
Gan-Lu-Yin (IRR:1.79), Shiee-Fuu-Jwu-Iu-Tang (IRR:1.69),
Sho-Yao-Gan-Cao-Tang (IRR:1.68), Chuan-Chung-Cha-
Tiao-San (IRR:1.59), Long-Dan-Xie-Gan-Tang (IRR:1.56),
Shu-Jing-Hwo-Shiee-Tang (IRR:1.56). By comparing the
increasing proportion ratio, the usage frequency of Ping-
Wei-San, Xiang-Sha-Liu-Jun-Zi-Tang Jia-Wei-Xia-Yao-San,
Xiao-Chai-Hu-Tang and Gan-Lu-Yin was significantly in-
creased after HCC diagnosis (P < 0.001) (Table 3).
Moreover, we compared the standardized incidence
rate ratio (IRR) obtained from the newly diagnosed HCC
patients who continuously used CHMs after HCC diag-
nosis for two years (n = 8,288; group 1-A). Our studies
also revealed a significant increasing proportion of usage
frequency in single Chinese herbs and Chinese herbal
formula two years after HCC diagnosis (P < 0.001). The
rating number of the top 10 single Chinese herbs or
Chinese herbal formulae of group 1-A was similar with
the total HCC patient group.
By adjusting with IRR, the increasing proportion of the
frequency of the top 10 single Chinese herbs prescribed in
newly diagnosed HCC patients who continuously used
CHMs after HCC diagnosis for two years (n = 8,288; group
1-A) were listed as: Oldenlandia diffusa (Bai-Hua-She-
She-Cao; IRR:2.39), Radix et Rhizoma Rhei (Da Huang;
IRR:2.32), Artemisia capillaris (Yin-Chen-Hao; IRR:2.04),
Scutellaria baicalensis (Huang-Qin; IRR:1.89), Astragalus
membranaceus (Huang-Qi; IRR:1.85), Salvia miltiorrhiza
(Dan-shen; IRR:1.73), Polygonum multiflorum Thunb
(IRR:1.72), Puerariae Radix (IRR:1.7), Fritillaria (Beimu;
IRR:1.67), Corydalis yanhusuo (Yanhusuo; IRR:1.61). By
comparing the increasing proportion ratio, the usage fre-
quency of Oldenlandia diffusa (Bai-Hua-She-She-Cao)
and Radix et Rhizoma Rhei (Da Huang) was significantly
increased after HCC diagnosis (P < 0.001).
The increasing proportion of use frequency of the top
10 Chinese herbal formulae prescribed in newly diag-
nosed HCC patients who continuously used CHMs after
HCC diagnosis for two years (n = 8,288; group 1-A) ac-
cording to IRR were listed as: Ping-Wei-San (IRR:1.89),
Xiang-Sha-Liu-Jun-Zi-Tang (IRR:1.83), Xiao-Chai-Hu-
Tang (IRR:1.77), Jia-Wei-Xia-Yao-San (IRR:1.67), Gan-
Table 3 The top 10 single Chinese herbs and Chinese herbal formula prescribed 2 years before and after HCC diagnosis by adjusting
with person-year during 2002-2009 (n = 73,918)
Frequency of CHM prescribed (every visit) IRR P value
2 years before HCC diagnosis 2 years after HCC diagnosis
n py IR n py IR
Single Chinese herbs Generic name (Chinese name)
3 Oldenlandia diffusa (Bai-Hua-She-She-Cao) 6,792 147,836 4.59 7,707 67,212 11.47 2.50 <0.001
8 Radix et Rhizoma Rhei (Da-Huan) 4,481 147,836 3.03 4,429 67,212 6.59 2.17 <0.001
5 Artemisia capillaris (Yin-Chen-Hao) 5,290 147,836 3.58 5,070 67,212 7.54 2.11 <0.001
4 Scutellaria baicalensis (Huang-Qin) 5,603 147,836 3.79 5,060 67,212 7.53 1.99 <0.001
7 Astragalus membranaceus (Huang-Qi) 4,677 147,836 3.16 4,042 67,212 6.01 1.90 <0.001
10 Polygonum multiflorum Thunb 3,994 147,836 2.7 3,398 67,212 5.06 1.87 <0.001
1 Salvia miltiorrhiza (Dan-shen) 9,558 147,836 6.47 7,827 67,212 11.65 1.80 <0.001
9 Puerariae Radix 4,148 147,836 2.81 3,383 67,212 5.03 1.79 <0.001
6 Fritillaria (Beimu) 5,246 147,836 3.55 4,093 67,212 6.09 1.72 <0.001
2 Corydalis yanhusuo (Yanhusuo) 7,902 147,836 5.35 5,909 67,212 8.79 1.64 <0.001
Chinese herbal formula (Chinese name)
6 Ping-Wei-San 5,093 147,836 3.45 4,563 67,212 6.79 1.97 <0.001
5 Xiang-Sha-Liu-Jun-Zi-Tang 5,963 147,836 4.03 5,304 67,212 7.89 1.96 <0.001
1 Jia-Wei-Xia-Yao-San 10,699 147,836 7.24 9,088 67,212 13.52 1.87 <0.001
2 Xiao-Chai-Hu-Tang 8,089 147,836 5.47 6,842 67,212 10.18 1.86 <0.001
8 Gan-Lu-Yin 4,962 147,836 3.36 4,040 67,212 6.01 1.79 <0.001
9 Shiee-Fuu-Jwu-Iu-Tang 4,731 147,836 3.2 3,633 67,212 5.41 1.69 <0.001
7 Sho-Yao-Gan-Cao-Tang 5,044 147,836 3.41 3,848 67,212 5.73 1.68 <0.001
10 Chuan-Chung-Cha-Tiao-San 4,688 147,836 3.17 3,379 67,212 5.03 1.59 <0.001
3 Long-Dan-Xie-Gan-Tang 6,803 147,836 4.6 4,835 67,212 7.19 1.56 <0.001
4 Shu-Jing-Hwo-Shiee-Tang 6,452 147,836 4.36 4,583 67,212 6.82 1.56 <0.001
Py person-year, IR standardized incidence rate, IRR the ratio of standardized incidence rate
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Lu-Yin (IRR:1.65), Sho-Yao-Gan-Cao-Tang (IRR:1.63),
Shu-Jing-Hwo-Shiee-Tang (IRR:1.59), Shiee-Fuu-Jwu-Iu-
Tang (IRR:1.55), Long-Dan-Xie-Gan-Tang (IRR:1.45),
Chuan-Chung-Cha-Tiao-San (IRR:1.59). By comparing
the increasing proportion ratio, our study revealed the
usage frequency of Ping-Wei-San, Xiang-Sha-Liu-Jun-Zi-
Tang, Xiao-Chai-Hu-Tang, Jia-Wei-Xia-Yao-San and
Gan-Lu-Yin was significantly increased after HCC diag-
nosis (P < 0.001).
Finally, we analyzed the use frequency and pattern of
the CHM prescribed 2 years before and after HCC diag-
nosis according to the code of ICD-9-CM. The study
find that patients with 2 years before HCC diagnosis, the
most common reason of the use of single herbal medi-
cine is chronic hepatitis and cirrhosis (ICD-9-CM: 573;
571), followed by chronic gastritis and chronic duoden-
itis (ICD-9-CM: 535) and nasopharyngeal and respira-
tory disease (ICD-9-CM: 786; 460). Compared with the
patients with 2 years after HCC diagnosis, the most
common reason of the use of single herbal medicine is
primary liver cancer (ICD-9-CM: 155), followed by
chronic hepatitis and cirrhosis (ICD-9-CM: 573; 571),
general symptoms (ICD-9-CM: 780) and respiratory dis-
ease (ICD-9-CM: 786). For the patients with 2 years be-
fore HCC diagnosis, the most common reason of the
use of Chinese herbal formula is chronic hepatitis and
cirrhosis (ICD-9-CM: 573; 571), followed by Stomach
dysfunction and chronic gastroduodenitis (ICD-9-CM:
535; 536), back pain (ICD-9-CM: 724) and acute naso-
pharyngitis (ICD-9-CM: 460). For the patients with 2 years
after HCC diagnosis, the most common reason of the use
of Chinese herbal formula is primary liver cancer (ICD-9-
CM: 155), followed by chronic hepatitis and cirrhosis
(ICD-9-CM: 573; 571), back pain (ICD-9-CM: 724) and
Acute nasopharyngitis (ICD-9-CM: 460) (Table 4).
Furthermore, for the study of frequency of CHM use,
the result showed the single Chinese herbs including
Oldenlandia diffusa (Bai-Hua-She-She-Cao), Radix et
Rhizoma Rhei (Da Huang), Scutellaria baicalensis
(Huang-Qin), Astragalus membranaceus (Huang-Qi),
Salvia miltiorrhiza (Dan-Shen), Corydalis yanhusuo
(Yanhusuo), Artemisia capillaris (Yin-Chen-Hao) and
Table 4 The use patterns of the top 10 single Chinese herbs and Chinese herbal formula prescribed before and after HCC diagnosis
according to the code of ICD-9-CM (n = 73,918)
Frequency of CHM use (every visit)
2 years before HCC diagnosis 2 years after HCC diagnosis
Rating n. Main ICD diagnosis Rating n. Main ICD diagnosis
Single Chinese herbs Generic name (Chinese name)
Salvia miltiorrhiza (Dan-Shen) 1 CLD*/cirrhosis (573; 571) 2 Primary liver cancer (155)
Corydalis yanhusuo (Yanhusuo) 2 Gastritis/duodenitis (535) 3 Primary liver cancer (155)
Oldenlandia diffusa (Bai-Hua-She-She-Cao) 3 CLD*/cirrhosis (573; 571) 1 Primary liver cancer (155)
Scutellaria baicalensis (Huang-Qin) 4 CLD*/cirrhosis (573; 571) 4 Primary liver cancer (155)
Fritillaria (Beimu) 5 Respiratory symptoms (786) 7 Respiratory symptoms (786)
Artemisia capillaris (Yin-Chen-Hao) 6 CLD*/cirrhosis (573; 571) 5 CLD*/cirrhosis (573; 571)
Astragalus membranaceus (Huang-Qi) 7 CLD*/cirrhosis (573; 571) 8 Primary liver cancer (155)
Puerariae Radix 8 Acute nasopharyngitis (460) 13 General symptoms (780)
Polygonum multiflorum Thunb 9 General symptoms (780) 15 General symptoms (780)
Radix et Rhizoma Rhei (Da Huan) 10 CLD*/cirrhosis (573; 571) 6 Primary liver cancer (155)
Chinese herbal formula (Chinese name)
Jia-Wei-Xia-Yao-San 1 CLD*/cirrhosis (573; 571) 1 CLD*/cirrhosis (573; 571)
Xiao-Chai-Hu-Tang 2 CLD*/cirrhosis (573; 571) 2 Primary liver cancer (155)
Long-Dan-Xie-Gan-Tang 3 CLD*/cirrhosis (573; 571) 4 CLD*/cirrhosis (573; 571)
Shu-Jing-Hwo-Shiee-Tang 4 Back disorders (724) 6 Back disorders (724)
Xiang-Sha-Liu-Jun-Zi-Tang 5 Stomach dysfunction (536) 3 Primary liver cancer (155)
Gan-Lu-Yin 6 Oral soft tissue disease (528) 7 Primary liver cancer (155)
Ping-Wei-San 7 Gastritis/duodenitis (535) 5 Primary liver cancer (155)
Chuan-Chung-Cha-Tiao-San 8 Acute nasopharyngitis (460) 12 Acute nasopharyngitis (460)
Sho-Yao-Gan-Cao-Tang 9 Back disorders (724) 10 Back disorders (724)
Shiee-Fuu-Jwu-Iu-Tang 10 CLD*/cirrhosis (573; 571) 14 CLD*/cirrhosis (573; 571)
CLD* Chronic liver disease
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the Chinese herbal formula including Ping-Wei-San,
Xiang-Sha-Liu-Jun-Zi-Tang, Xiao-Chai-Hu-Tang, Jia-Wei-
Xia-Yao-San and Gan-Lu-Yin were significantly increased
in use frequency After HCC diagnosis. Therefore, we con-
cluded that Oldenlandia diffusa (Bai-Hua-She-She-Cao),
Radix et Rhizoma Rhei (Da Huang), Ping-Wei-San, Xiang-
Sha-Liu-Jun-Zi-Tang, Xiao-Chai-Hu-Tang, Jia-Wei-Xia-
Yao-San and Gan-Lu-Yin are more important CHMs for
treatment of HCC in our study.
Althought the National health insurance (NHI) is the
only national and official health insurance program and
covers nearly all inhabitants in Taiwan. Nearly all of the
inhabitants use the NHI care system to treat the disease,
which also includes traditional Chinese medicine ther-
apy. Therefore, The patients accessing CHMs in the
Chinese herbal store and other medical institutions at
their own expense would be few. In any case, this is an
unavoidable limitation of our study.
Discussion
CHMs have been used as traditional medicine with po-
tent historical and cultural reasons in the Western Pa-
cific Region for health maintenance, disease prevention,
and even disease treatment for thousands of years. In
addition, the use of CHMs is becoming more popular in
other countries where it is used as an alternative to, or
complementary with, Western medicine [20] and been
proven to be an efficacious and harmless treatment
option for chronic hepatitis and cirrhosis in some clin-
ical trials [14, 15]. In some pilot studies, CHMs have
been proven beneficial for preventing and treating HCC
[16, 17]. However, despite of CHMs having been used
for HCC treatment for thousand of years, it remains un-
clear what kind of single Chinese herbs or formulae used
would possibly be effective in treating HCC in clinical
practice. Moreover, there were little large-scale epi-
demiological studies or evidence-based studies evaluat-
ing the frequency and patterns of drug utilization of
CHM in treating HCC. Thus far, it is hard to reach an
unanimity or establish a general guideline of CHM pre-
scription for treatment of HCC. In this study, we found
that more than 20% of patients use of single herbal drug
or Chinese herbal formula prior to the HCC diagnosis.
Even in the two years after HCC diagnosed, there are
still up to 15–17% of patients using CHMs. Clearly, the
use of CHMs plays an important role in the treatment of
HCC. Therefore, it is very important in the further study
of use pattern and model of Chinese medicine practi-
tioners in the HCC treatment and disease control. To
our knowledge, our study is the first large-scale epi-
demiological study and is focused on the frequency and
patterns of drug utilization of CHM in treating HCC.
In Traditional Chinese Medicine (TCM) theory, the
clinical diagnosis and treatment in TCM are chiefly
based on the yin-yang and five elements theories, wood,
fire, earth, metal, and water: an antique philosophical
opinion used to clarify the composition and phenomena
of the physical macrocosm. These theories administer
the phenomena and rule of nature to the study of the
physiological actions and pathological changes of the hu-
man body and its interrelationships [21]. Based on these
theories, liver is considered the “the general of an army,
which stores the blood, controls the sinews and main-
tains a smooth and uninterrupted flow of Qi”. The dis-
order of the liver, defined as「liver depression and
spleen deficiency, blood stasis and phlegm coagulation,
lead to liver depression with Qi stagnation, blood and Qi
stagnation and water retention, and a syndrome of inter-
mingled vacuity and repletion」, may extraordinarily
affect the whole body and lead to liver fibrosis, cirrhosis
or HCC [22].
In the past decades, phytochemistry and molecular
biology advances have been widely applied to elucidate the
material foundation and pharmacological mechanisms of
TCM in fighting HCC. In the literature review, several
representative herbal compounds, such as curcumin, res-
veratrol, silibinin, berberine, quercetin, tanshinoneII-A
and celastrol, from CHMs have been documented as hav-
ing an anti-HCC effect [21, 22]. However, the CHM con-
tains hundreds of medicinal substances, including plants,
some minerals and animal products classified by their per-
formed function in the body. Different parts of CHM such
as the leaves, roots, stems, flowers, and seeds are widely
used. Many single Chinese herbs, such as Dan-shen,
Huanglian, Scutellaria baicalensis, Andrographis panicu-
lata …have been proven to have an anti-HCC effect in
basic and clinical study [21–24]. Many Chinese herbal for-
mulas, such as Songyou Yin Formula, Jiedu-Xiaozheng
Yin Formula, JDF granules, Bu-Zhong-Yi-Qi-Tang … have
also been proven to have an anti-HCC effect in basic and
clinical research [21, 22, 25]. However, the majority of
CHMs use to treat HCC was based on the physician’s em-
pirical experiences, and it remains unclear what kind of
single Chinese herbs or formulae used would possibly be
effective in treating HCC in evidence-based practice.
In the present study, we analyzed the actual drug
utilization frequency and prescribing patterns of CHMs
use in Taiwan by licensed Chinese medicine Physicians.
Our result showed the single Chinese herbs, Oldenlandia
diffusa (Bai-Hua-She-She-Cao), Radix et Rhizoma Rhei
(Da Huang) and the Chinese herbal formulas, Ping-Wei-
San, Xiang-Sha-Liu-Jun-Zi-Tang, Xiao-Chai-Hu-Tang, Jia-
Wei-Xia-Yao-San and Gan-Lu-Yin, were frequently used
CHMs for treating HCC.
HCC has known association with multiple risk factors,
and its precursors have demonstrated complex and hetero-
geneous genetic or chromosomal abnormalities. HCC is a
well known phenotypically and genetically heterogenous
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tumor [26]. Carcinogenesis of hepatocarcinoma is a multi-
factor, multi-step and complex process. It involves three
distinguishable but closely connected stages: initiation
stage (normal cell→ transformed or initiated cell), promo-
tion stage (initiated cell→ preneoplastic cell), and progres-
sion stage (preneoplastic cell→ neoplastic cell) [27].
Malignant transformation of hepatocytes may occur, re-
gardless of the etiological agent, through a pathway of in-
creased liver cell turnover, induced by chronic liver injury
and regeneration in a context of inflammation, immune
response, and oxidative DNA damage [28–30].
Since ancient times, many natural products, herbs and
spices have been used as remedies for various diseases
and cancers. Recently, these agents were used as a
pharmacological intervention aimed to arrest or reverse
the process of carcinogenesis [31]. It has been recog-
nized that many single Chinese herbs may be sufficient
to provide chemopreventive efficacy for HCC. According
to literature review, water extract of Hedyotis Diffusa
Willd (Bai-Hua-She-She-Cao) was found remarkably
inhibited HepG2 cell proliferation via arrest of HepG2
cells at the G0/G1 phase and induction of S phase delay
[32]; Radix et Rhizoma Rhei (Da Huang) was found to
inhibit the human hepatoma cell line (SMMC-7721
cells) in G2/M phase increased significantly, while the
proportion of S phase cells gradually declined [33]; In
vivo study reported that Scutellaria baicalensis (Huang-
Qin) exerts a broad effect on cell signaling networks and
G2/M phase arrest leading to a collective inhibition of
HepG2 cells proliferation [23]; Astragalus membrana-
ceus (Huang-Qi) was reported to improve the function
of T lymphocytes in cancer patients [34]; Salvia miltior-
rhiza (Dan-Shen) was reported to inhibit Hep-J5 cells
and induce apoptosis through novel molecular targets,
calreticulin, caspase 12 and GADD153 [35]; The Coryd-
alis yanhusuo (Yanhusuo) extract, which might be medi-
ated by inducing reactive oxygen species formation and
decreasing mitochondrial membrane potential expres-
sions, was reported to inhibit MCF-7 proliferation by in-
ducing G2/M cell cycle arrest [36]; Artemisia capillaris
(Yin-Chen-Hao) is recognized not only as a hepatopro-
tective agent for various types of liver diseases but also
served as a potential anti-cancer drug by inducing apop-
tosis in HepG2 cells via activation of caspase and mito-
chondria pathway [37]; The water extracts of Polygonum
multiflorum Thunb root was reported to aid against
HEP G2 Hepatocarcinoma Cell Proliferation by activa-
tion of caspase-8, caspase-9, and caspase-3 [38]; Puerar-
iae Radix was reported to inhibit growth and induce
apoptosis in SMMC-772 hepatocellular carcinoma cells
via the mitochondria-dependent pathway [39].
Furthermore, it has been recognized that many Chinese
herbal formulas may be sufficient to provide hepatopro-
tectant and chemopreventive efficacy for HCC patients by
literature review. Traditionally, Chinese herbal formulas
were most commonly used for immunological restoration,
harmonizing gastrointestinal function, hepato-protectant,
and even reported to have anti-tumor effects. According
to literature review, Ping-Wei-San and Xiang-Sha-Liu-Jun-
Zi-Tang are widely used in spleen-stomach Qi deficiency
and as symptomatic disease control. Xiao-Chai-Hu-Tang,
a known hepatoprotectant agent, has been found to inhibit
the development of hepatocellular carcinoma by inhibiting
the activation of stellate cells [40]. Jia-Wei-Xia-Yao-San,
used as an adjunctive therapy combined with RFA, TACE
or conventional chemotherapy agent, maybe increase the
survival in liver cancer patients [41]. Gan-Lu-Yin has an
inhibitory effect on angiogenesis, which in turn may pre-
vent tumor growth, and its mechanism might be partially
associated with blocking VEGF protein expression of hu-
man umbilical vein endothelial cells (HUVEC) [42]. Shiee-
Fuu-Jwu-Iu-Tang is believed to work mainly through the
removal of blood stasis and promotion of circulation in
tissues and organs, and an increase in tissue oxygen-blood
perfusion [43]. Recent advances found Shiee-Fuu-Jwu-Iu-
Tang combined with mitomycin C increased the mean
survival time of liver tumor-bearing mice [44]. Long-Dan-
Xie-Gan-Tang, a famous Chinese herbal formula with
potent anti-inflammation, anti-oxidation, immune modu-
lation, anti-herpetic virus, and anti-HBV properties, also
found limited clinical anti-cancer properties in some clin-
ical practical reports [45].
However, our findings are not correlated with previous
literature reports. The reasons are: (1) unlike the past
researches that focus on chronic hepatitis or cirrhosis
[12, 21], the aim of our study is focus on the real
change of CHMs before and after HCC diagnosis; (2)
our results had been adjusted by excluding patients of
HCC who died within two years after HCC diagnosis
and (3) The rating numbers of CHMs in our study
was adjusted by using person-year and ratio of stan-
dardized incidence rate. As a result, our study con-
ducted the actual prescription frequency and patterns
of CHMs usage of licensed Chinese medicine Physi-
cians in Taiwan. Therefore, the results of our study
showed that, first, the single Chinese herbs, such as
Oldenlandia diffusa (Bai-Hua-She-She-Cao); Radix et
Rhizoma Rhei (Da Huang); Scutellaria baicalensis
(Huang-Qin); Astragalus membranaceus (Huang-Qi);
Salvia miltiorrhiza (Dan-Shen); Corydalis yanhusuo
(Yanhusuo); Artemisia capillaris (Yin-Chen-Hao); Pol-
ygonum multiflorum Thunb; Puerariae Radix and the
Chinese herbal formulas, such as Xiao-Chai-Hu-Tang
and Gan-Lu-Yin, were frequently used for treatment
of liver cancer clinically and were also approved by
basic research. At the same time, compared with the
use frequency of CHMs, the use frequency of these
CHMs is also increased significantly after HCC
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diagnosed. Second, the Chinese herbal formulas, such
as Jia-Wei-Xia-Yao-San; Shiee-Fuu-Jwu-Iu-Tang; Long-
Dan-Xie-Gan-Tang, had been used to prolong the life span
of patients with HCC or chronic liver disease or as an ad-
juvant therapy for HCC patients after traditional Western
medicine treatment. However, the evidence of approval of
anti-cancer effects and basic research of these CHMs
needs further investigations. Thus, it is still the need for
further researches in these CHMs. Third, the single
Chinese herbal drugs, Fritillaria (Beimu), and the Chinese
herbal formulas, Ping-Wei-San and Xiang-Sha-Liu-Jun-Zi-
Tang, were used mainly in spleen-stomach Qi deficiency
and as symptomatic disease control. There was no evi-
dence of approval of anti-cancer effect for Fritillaria
(Beimu), Ping-Wei-San and Xiang-Sha-Liu-Jun-Zi-Tang,
accorded to our literature review. At last, our study sug-
gested that, Oldenlandia diffusa (Bai-Hua-She-She-Cao),
Radix et Rhizoma Rhei (Da Huang) and the herbal prepar-
ation of Xiao-Chai-Hu-Tang and Gan-Lu-Yin, were the
most obviously increased and important CHMs been used
for patients after HCC diagnosis.
Conclusion
In this study, we developed an accurate and validated
method for the actual frequency and patterns of CHM
use in treating HCC in Taiwan. By adjusting with cumu-
lative survival, person-year and the ratio of standardized
incidence rate, we can accurately know the common and
effective prescriptions used by Chinese medicine physi-
cians in the treatment of liver cancer. In addition, the
study found that the single herbal drug of Oldenlandia
diffusa (Bai-Hua-She-She-Cao), Radix et Rhizoma
Rhei (Da Huang) and Chinese herbal formula of Xiao-
Chai-Hu-Tang and Gan-Lu-Yin are the most commonly
used prescriptions in the treatment of HCC. This finding
is also consistent with the results of previous basic re-
searches. We believe that the findings of this study can
be provided as physician reference of CHM selection
and clinical research for the treatment of liver cancer.
This could be first step to assess the efficacy of CHM
which could be recommended to treat or prevent the
HCC in general and especially for the HCC patients
from Taiwan. In the future, our study can be developed
as a following principle and reference of clinical trials of
CHMs in cancer treatment [46].
In Conclusion, we established an accurate and vali-
dated method for the actual frequency and patterns of
CHM use in treating HCC in Taiwan. We propose that
these breakthrough findings may have important impli-
cations for HCC therapy, clinical trials and
modernization of CHM. However, further basic re-
searches and clinical trials are required to evaluate the
mechanism, efficacy and safety, and to develop new
treatments strategies of CHMs in treating HCC.
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